Myriad Genetics Files 8-K on Security Holder Vote

TL;DR

MYGN shareholders voting on key issues June 6th.

AI Summary

Myriad Genetics, Inc. filed an 8-K on June 6, 2024, to report on the submission of matters to a vote of security holders. The filing does not contain specific details about the matters to be voted on or any financial figures.

Why It Matters

This filing indicates that Myriad Genetics is convening a meeting where shareholders will vote on important company matters, which could impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes.

Key Players & Entities

• MYRIAD GENETICS INC (company) — Registrant
• June 6, 2024 (date) — Date of earliest event reported
• 0000899923-24-000028 (filing_id) — Accession Number

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar

Filing Documents

• mygn-20240606.htm (8-K) — 44KB
• 0000899923-24-000028.txt ( ) — 192KB
• mygn-20240606.xsd (EX-101.SCH) — 2KB
• mygn-20240606_def.xml (EX-101.DEF) — 14KB
• mygn-20240606_lab.xml (EX-101.LAB) — 25KB
• mygn-20240606_pre.xml (EX-101.PRE) — 15KB
• mygn-20240606_htm.xml (XML) — 3KB

07 Submissions of Matters to a Vote of Security Holders

ITEM 5.07 Submissions of Matters to a Vote of Security Holders On June 6, 2024, Myriad Genetics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Of the 90,478,255 shares of Company common stock outstanding as of the record date of April 11, 2024, a quorum of 84,424,257 shares, or approximately 93% of the outstanding shares of Company common stock, was present via webcast or represented by proxy. The following is a brief description of each matter submitted to a vote at the Annual Meeting, as well as the number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter. Proposal No. 1: Election of Directors Votes Votes Votes Broker For Against Abstained Non-Votes S. Louise Phanstiel 72,176,819 6,303,679 44,684 5,899,075 Daniel M. Skovronsky 77,928,386 557,211 39,585 5,899,075 Each of S. Louise Phanstiel and Daniel M. Skovronsky was elected to serve as a director of the Company for a term expiring at the 2027 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal. Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 Votes Votes Votes For Against Abstained 81,454,833 2,917,829 51,595 The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved by stockholders. Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes 74,410,679 4,060,490 54,013 5,899,075 The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement,

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: June 6, 2024 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR